Skip to main content
Premium Trial:

Request an Annual Quote

AltheaDx, Compendia Partner on Breast Cancer Assay

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AltheaDx today said that it has formed a partnership with Compendia Bioscience to combine their technologies to create tests that can predict patient outcomes in clinical trials.

The initial product developed under the collaboration is the Breast Cancer Segregation Panel Assay — a real-time, PCR-based panel that has been optimized for analysis of RNA extracted from formalin-fixed, paraffin-embedded tissue. The panel includes 96 genes associated with breast cancer identified through a meta-analysis of cancer genomic data from more than 5,000 clinical samples, said AltheaDx.

Under the collaboration, AltheaDx will process and analyze samples at its San Diego-based CLIA and GLP lab. Compendia will manage downstream data analysis and statistical correlation to patient outcomes in clinical trials.

The firms also said that they plan to develop Segregation Panels for other cancer types, with the launch of a Colorectal Cancer Segregation Panel expected to be launched in 2011.

Further terms of the alliance were not disclosed.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.